1. Patel MD, Coshall C, Rudd AG, Wolfe CD. Cognitive impairment after stroke: clinical determinants and its associations with long‐term stroke outcomes. Journal of the American Geriatrics Society. 2002;50(4):700-6.
2. Wagle J, Farner L, Flekkoy K, Bruun Wyller T, Sandvik L, Fure B, et al. Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. Dement Geriatr Cogn Disord. 2011;31(5):379-87.
3. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2(8):80.
4. Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573-91.
5. Ding MY, Xu Y, Wang YZ, Li PX, Mao YT, Yu JT, et al. Predictors of Cognitive Impairment After Stroke: A Prospective Stroke Cohort Study. J Alzheimers Dis. 2019;71(4):1139-51.
6. Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. Nat Rev Neurol. 2017;13(3):148-59.
7. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.
8. Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, et al. Phosphorylated tau interactome in the human Alzheimer's disease brain. Brain. 2020;143(9):2803-17.
9. Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B. Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Netw Open. 2020;3(12):e2028634.
10. Tang S-C, Yang K-C, Chen C-H, Yang S-Y, Chiu M-J, Wu C-C, et al. Plasma β-amyloids and tau proteins in patients with vascular cognitive impairment. Neuromolecular medicine. 2018;20(4):498-503.
11. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-33.
12. Liu W, Wang X, O'Connor M, Wang G, Han F. Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities. Neural Plast. 2020;2020:1969482.
13. Stanne TM, Åberg ND, Nilsson S, Jood K, Blomstrand C, Andreasson U, et al. Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. Stroke. 2016;47(7):1943-5.
14. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-6.
15. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73(21):1759-66.
16. Tsai CF, Lee WJ, Wang SJ, Shia BC, Nasreddine Z, Fuh JL. Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis. Int Psychogeriatr. 2012;24(4):651-8.
17. Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke–Canadian Stroke Network vascular cognitive impairment harmonization standards neuropsychological battery after tia and stroke. Stroke. 2012;43(2):464-9.
18. Lynch CA, Walsh C, Blanco A, Moran M, Coen RF, Walsh JB, et al. The clinical dementia rating sum of box score in mild dementia. Dement Geriatr Cogn Disord. 2006;21(1):40-3.
19. Chi N-F, Chao S-P, Huang L-K, Chan L, Chen Y-R, Chiou H-Y, et al. Plasma amyloid beta and tau levels are predictors of post-stroke cognitive impairment: A longitudinal study. Frontiers in Neurology. 2019;10:715.
20. Turunen KE, Laari SP, Kauranen TV, Uimonen J, Mustanoja S, Tatlisumak T, et al. Domain-specific cognitive recovery after first-ever stroke: a 2-year follow-up. Journal of the International Neuropsychological Society. 2018;24(2):117-27.
21. Wang HH, Li HL, Liu R, Zhang Y, Liao K, Wang Q, et al. Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. J Alzheimers Dis. 2010;21(1):167-79.
22. Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70(3):410-26.
23. Bateman RJ, Barthélemy NR, Horie K. Another step forward in blood-based diagnostics for Alzheimer’s disease. Nature Medicine. 2020:1-2.
24. Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K. Post-translational modifications of tau protein. Bratisl Lek Listy. 2006;107(9-10):346-53.
25. Hagberg G, Ihle-Hansen H, Fure B, Thommessen B, Ihle-Hansen H, Øksengård AR, et al. No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke-a seven-year follow-up study. BMC neurology. 2020;20:1-11.
26. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience letters. 2001;297(3):187-90.
27. Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Åberg ND, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. Journal of Central nervous system Disease. 2014;6:JCNSD. S13821.
28. Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18.
29. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011;7(3):270-9.
30. Avila J, León-Espinosa G, García E, García-Escudero V, Hernández F, DeFelipe J. Tau phosphorylation by GSK3 in different conditions. International Journal of Alzheimer’s Disease. 2012;2012.
31. Fandos N, Pérez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179-87.
32. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-60.
33. Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA, et al. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's & Dementia. 2018;14(3):280-92.
34. Wyman‐Chick KA, Scott B. Development of Clinical Dementia Rating Scale Cut‐off Scores for Patients With Parkinson's Disease. Movement disorders clinical practice. 2015;2(3):243-8.
35. Abzhandadze T, Rafsten L, Lundgren Nilsson ÅC, Palstam A, Sunnerhagen KS. Very early MoCA can predict functional dependence at 3 months after stroke: A longitudinal, cohort study. Frontiers in neurology. 2019;10:1051.
36. del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, et al. Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke. 2005;36(12):2670-5.
37. Pluta R. The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemia-reperfusion brain injury. A model of early Alzheimer's disease. Ann N Y Acad Sci. 2000;903:324-34.